Demographic, clinical and treatment characteristics of patients with Kaposi’s sarcoma: A single-center study

Year 2019, Volume: 32 Issue: 2, 86 - 89, 31.05.2019

Andac Salman , Zuleyha Ozgen

https://doi.org/10.5472/marumj.572716

Cited By: 1

Abstract

Objective:
The clinical,
demographic and treatment characteristics of patients with Kaposi’s sarcoma
(KS) are not well-defined. There is lack of consensus on treatment modalities.
Thus, we aimed to define demographic, clinical characteristics and treatment
outcomes in our cohort of patients with KS.

       Patients and Methods: A retrospective cohort study was
done and all patients who were followed up in our specialized cutaneous tumors
outpatient clinic with a diagnosis of KS between 2006 and 2018 were included in
the study.

       Results: A total of 25 patients were included
in the study. The mean age of the patients was 66 and 80% were male. The most
common form of KS was classic type (80%). During a mean follow-up of 43 months,
the most frequently administered treatments were cryotherapy, interferons,
radiotherapy, topical imiquimod and topical timolol. Overall a complete
response was observed in 9 (36%) patients.

        Conclusion: The clinical and demographic
characteristics of our cohort match those observed in existing literature. We
think that the use of local treatments such as cryotherapy, topical imiquimod
should be used more frequently in patients with limited disease. Considering
the efficacy of timolol in other vascular tumors, future prospective studies
investigating the effects of timolol in KS are highly warranted.

Keywords

Cryotherapy, Kaposi’s sarcoma, Timolol, Treatment

References

• 1. Geraminejad P, Memar O, Aronson I, Rady PL, Hengge U, Trying SK. Kaposi’s sarcoma and other manifestations of human herpesvirus 8. J Am Acad Dermatol 2002; 47:641-55. doi: 10.1067/mjd.2002.128383
• 2. Cesarman E, Damania B, Krown SE, Martin J, Bower M, Whitby D. Kaposi sarcoma. Nat Rev Dis Primers 2019; 5:9. doi: 10.1038/s41572.019.0060-9
• 3. Feuerman EJ, Potruch-Eisenkraft S. Kaposi’s sarcoma. A follow-up of 38 patients. Dermatologica 1973; 146:115-22. doi: 10.1159/000252034
• 4. Schneider JW, Dittmer DP. Diagnosis and treatment of Kaposi sarcoma. Am J Clin Dermatol 2017; 18:529-39. doi: 10.1007/s40257.017.0270-4
• 5. Kandaz M, Bahat Z, Guler OC, Canyilmaz E, Melikoglu M, Yoney A. Radiotherapy in the management of classic Kaposi’s sarcoma: A single institution experience from Northeast Turkey. Dermatol Ther 2018; 31:1-4. doi: 10.1111/ dth.12605
• 6. Chalya PL, Mbunda F, Rambau PF, et al. Kaposi’s sarcoma: A 10-year experience with 248 patients at a single tertiary care hospital in Tanzania. BMC Res Notes 2015; 8:1–10. doi: 10.1186/s13104.015.1348-9
• 7. Tiussi RM, Caus AL de O, Diniz LM, Lucas EA. Kaposi’s sarcoma: clinical and pathological aspects in patients seen at the Hospital Universitário Cassiano Antônio Moraes – Vitória – Espírito Santo – Brazil. An Bras Dermatol 2012; 87:220–7. doi: 10.1590/S0365.059.6201200.020.0005
• 8. Errihani H, Berrada N, Raissouni S, Rais F, Mrabti H, Rais G. Classic Kaposi’s sarcoma in morocco: Clinico – epidemiological study at the national institute of oncology. BMC Dermatol 2011; 11:15. doi: 10.1186/1471-5945-11-15
• 9. Wu X-J, Kang X-J, An C-X, et al. One hundred and five Kaposi sarcoma patients: a clinical study in Xinjiang, Northwest of China. J Eur Acad Dermatol Venereol 2013; 28:1545–52. doi: 10.1111/jdv.12349
• 10. Trinca S, Ricci P, Benedetti M, Trinca S, Ricci P, Comba P. High incidence of classic Kaposi’s sarcoma in Mantua, Po Valley, Northern Italy (1989–1998). Br J Cancer 2002; 85:379–82. doi: 10.1054/bjoc.2001.1912
• 11. Su Ö, Onsun N, Arda H, Ümmetoğlu Ö, Pekdemir A. Clinical Features, Presence of Human Herpesvirus-8 and Treatment Results in Classic Kaposi Sarcoma. TURKDERM – Arch Turkish Dermatology Venerol 2008; 42:122-6
• 12. Gülüş Demirel B, Koca R, Solak Tekin N, Onak Kandemir N, Doğan Gün B, Köktürk F. Classic Kaposi’s sarcoma: The clinical, demographic and teratment characteristics of seventy-four patients. TURKDERM – Arch Turkish Dermatology Venerol 2016; 50:136–40. doi: 10.4274/ turkderm.35336
• 13. Demirkazik A, Ozal G, Yildirim Ozdemir N, et al. Fifty-one Kaposi sarcoma patients. Clin Transl Oncol 2010; 12:629– 33. doi: 10.1007/s12094.010.0568-7
• 14. Laresche C, Fournier E, Dupond AS, et al. Kaposi’s sarcoma: a population-based cancer registry descriptive study of 57 consecutive cases diagnosed between 1977 and 2009. Int J Dermatol 2014; 53:e549–54. doi: 10.1111/ijd.12453
• 15. Cottoni F, Masala MV, Piras P, Montesu MA, Cerimele D. Mucosal involvement in classic Kaposi’s sarcoma. Br J Dermatol 2003; 148:1273–4. doi: 10.1046/j.1365- 2133.2003.05359.x
• 16. DiGiovanna JJ, Safai B. Kaposi’s sarcoma. Retrospective study of 90 cases with particular emphasis on the familial occurrence, ethnic background and prevalence of other diseases. Am J Med 1981; 71:779–83. doi: 10.1016/0002- 9343(81)90356-9
• 17. Régnier-Rosencher E, Guillot B, Dupin N. Treatments for classic Kaposi sarcoma: A systematic review of the literature. J Am Acad Dermatol 2013; 68:313–31. doi: 10.1016/j. jaad.2012.04.018
• 18. Alcántara-Reifs CM, Salido-Vallejo R, Garnacho-Saucedo GM, Vélez García-Nieto A. Classic Kaposi’s sarcoma treated with topical 0.5% timolol gel. Dermatol Ther 2016; 29:309– 11. doi: 10.1111/dth.12381
• 19. Meseguer-Yebra C, Cardeñoso-Álvarez ME, Bordel-Gómez MT, Fraile-Alonsı MC, Perez-Losada ME, Sanchez-Estella J. Successful treatment of classic Kaposi sarcoma with topical timolol: report of two cases. Br J Dermatol 2015; 173:860–2. doi: 10.1111/bjd.13746
• 20. Chap S, Vu M, Robinson AJ, Braue A, Varigos GA, Scardamaglia L. Treatment of cutaneous iatrogenic Kaposi sarcoma with topical timolol. Australas J Dermatol 2017; 58:242–3. doi: 10.1111/ajd.12650
• 21. Abdelmaksoud A, Filoni A, Giudice G, Vestita M. Classic and HIV-related Kaposi sarcoma treated with 0.1% topical timolol gel. J Am Acad Dermatol 2017; 76:153–5. doi: 10.1016/j.jaad.2016.08.041
• 22. Puttgen K, Lucky A, Adams D, et al. Topical Timolol Maleate Treatment of Infantile Hemangiomas. Pediatrics 2016; 138:e20160355–e20160355. doi: 10.1542/peds.2016- 035529:309–11
• 23. Puttgen K, Lucky A, Adams D, et al. Topical Timolol Maleate Treatment of Infantile Hemangiomas. Pediatrics 2016; 138:e20160355–e20160355